Anemia in CKD in Primary Care: Executive Summary.
作者信息
Brunton Stephen, Fishbane Steven, Goldman Jennifer D, Wright Eugene
机构信息
Primary Care Metabolic Group, Winnsboro, SC.
Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, NY.
出版信息
Clin Diabetes. 2022 Winter;41(1):81-84. doi: 10.2337/cd22-0054. Epub 2022 Sep 9.
Abstract
摘要
相似文献
1
Anemia in CKD in Primary Care: Executive Summary.
Clin Diabetes. 2022 Winter;41(1):81-84. doi: 10.2337/cd22-0054. Epub 2022 Sep 9.
2
Impact of chronic kidney disease and anemia on health-related quality of life and work productivity: analysis of multinational real-world data.
BMC Nephrol. 2020 Mar 7;21(1):88. doi: 10.1186/s12882-020-01746-4.
3
Patient and Care Partner Burden in CKD Patients With and Without Anemia: A US-Based Survey.
Kidney Med. 2022 Mar 7;4(4):100439. doi: 10.1016/j.xkme.2022.100439. eCollection 2022 Apr.
4
Poor recognition and undertreatment of anemia in patients with chronic kidney disease managed in primary care.
J Intern Med. 2023 Nov;294(5):628-639. doi: 10.1111/joim.13702. Epub 2023 Aug 4.
5
The prevalence and recognition of chronic kidney disease and anemia in long-term care residents.
Consult Pharm. 2012 Sep;27(9):627-40. doi: 10.4140/TCP.n.2012.627.
6
Improving Detection and Management of Anemia in CKD.
J Fam Pract. 2022 Jul;71(6 Suppl):S23-S28. doi: 10.12788/jfp.0411.
7
Iron-Deficiency Anemia in CKD: A Narrative Review for the Kidney Care Team.
Kidney Med. 2023 May 25;5(8):100677. doi: 10.1016/j.xkme.2023.100677. eCollection 2023 Aug.
8
Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: Design and baseline characteristics.
Am Heart J. 2021 May;235:1-11. doi: 10.1016/j.ahj.2020.10.068. Epub 2020 Oct 30.
9
Prognostic impact of chronic kidney disease and anemia at admission on in-hospital outcomes after primary percutaneous coronary intervention for acute myocardial infarction.
Int Heart J. 2014;55(4):301-6. doi: 10.1536/ihj.13-367. Epub 2014 Jun 2.
10
Prevalence, etiology, and consequences of anemia and clinical and economic benefits of anemia correction in patients with chronic kidney disease: an overview.
Am J Health Syst Pharm. 2007 Jul 1;64(13 Suppl 8):S3-7; quiz S23-5. doi: 10.2146/ajhp070181.
本文引用的文献
1
Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis.
N Engl J Med. 2021 Dec 16;385(25):2313-2324. doi: 10.1056/NEJMoa2113380. Epub 2021 Nov 5.
2
Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.
N Engl J Med. 2021 Dec 16;385(25):2325-2335. doi: 10.1056/NEJMoa2113379. Epub 2021 Nov 5.
3
A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.
Kidney Int Rep. 2021 Apr 17;6(7):1829-1839. doi: 10.1016/j.ekir.2021.04.007. eCollection 2021 Jul.
4
Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES).
Nephrol Dial Transplant. 2021 Aug 27;36(9):1616-1628. doi: 10.1093/ndt/gfab191.
5
Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis.
N Engl J Med. 2021 Apr 29;384(17):1601-1612. doi: 10.1056/NEJMoa2025956.
6
Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD.
N Engl J Med. 2021 Apr 29;384(17):1589-1600. doi: 10.1056/NEJMoa2035938.
7
Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease.
Kidney Int Suppl (2011). 2021 Apr;11(1):8-25. doi: 10.1016/j.kisu.2020.12.002. Epub 2021 Mar 18.
8
Anemia of chronic kidney disease: Protocol of study, management and referral to Nephrology.
Nefrologia (Engl Ed). 2018 Jan-Feb;38(1):8-12. doi: 10.1016/j.nefro.2017.09.004. Epub 2017 Nov 9.
9
Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD.
Am J Kidney Dis. 2017 Jun;69(6):815-826. doi: 10.1053/j.ajkd.2016.12.011. Epub 2017 Feb 24.
10
Prevalence of anemia in chronic kidney disease in the United States.
PLoS One. 2014 Jan 2;9(1):e84943. doi: 10.1371/journal.pone.0084943. eCollection 2014.
Zotero 插件